Emna Kerkeni
Overview
Explore the profile of Emna Kerkeni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chadli Z, Hannachi I, Ben Belgacem M, Guediche A, Ben Romdhane H, Kerkeni E, et al.
Pharmacogenomics
. 2024 Oct;
25(10-11):441-450.
PMID: 39382000
Thiopurine drugs are used in the treatment of various diseases including inflammatory bowel disease. Thiopurine-S-methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) are the crucial enzymes involved in thiopurines metabolism. The...
2.
Hannachi I, Chadli Z, Kerkeni E, Chaabane A, Ben-Fredj N, Boughattas N, et al.
Tunis Med
. 2024 Sep;
102(9):537-542.
PMID: 39287345
Introduction: Human cytochrome P450 (CYP), particularly CYP3A4 and CYP3A5 is mainly responsible for the metabolism of several drugs including tacrolimus. Significant interracial/interethnic variation in the expression and function of CYP3A5...
3.
Alshaikheid M, Ben Fredj N, Hannachi I, Kolsi N, Ben Fadhel N, Kerkeni E, et al.
Pharmacogenomics J
. 2021 Mar;
21(4):467-475.
PMID: 33649521
This study aimed to develop a population pharmacokinetic model using full pharmacokinetic (PK) profiles of isoniazid (INH) taking into account demographic and genetic covariates and to develop Bayesian estimators for...
4.
Hannachi I, Chadli Z, Kerkeni E, Kolsi A, Hammouda M, Chaabane A, et al.
Pharmacogenomics J
. 2020 Sep;
21(1):107.
PMID: 32908236
No abstract available.
5.
Hannachi I, Chadli Z, Kerkeni E, Kolsi A, Hammouda M, Chaabane A, et al.
Pharmacogenomics J
. 2020 Aug;
21(1):69-77.
PMID: 32843687
Tacrolimus is characterized by a highly variable pharmacokinetics (PK) and a small therapeutic window. It is metabolized specifically by the CYP3A isoenzymes. This study aimed to determine, in kidney transplant...
6.
Ghedira N, Lagarde A, Ben Ameur K, Elouej S, Sakka R, Kerkeni E, et al.
BMC Pediatr
. 2018 Aug;
18(1):286.
PMID: 30157809
Background: Noonan syndrome (NS) is an autosomal dominant multisystem disorder caused by the dysregulation of several genes belonging to the RAS Mitogen Activated Protein Kinase (MAPK) signaling pathway. Incontinentia Pigmenti...
7.
Chadli Z, Kerkeni E, Hannachi I, Chouchene S, Ben Fredj N, Boughattas N, et al.
Ther Drug Monit
. 2018 Aug;
40(5):655-659.
PMID: 30086084
Thiopurine-S-methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) are crucial enzymes involved in the metabolism of thiopurine drugs. Significant interethnic variation in the expression of TPMT and ITPA is caused by...
8.
Chadli Z, Ladhari C, Kerkeni E, Djobbi A, Fredj N, Chaabane A, et al.
Pharmacogenomics
. 2018 Jun;
19(11):889-893.
PMID: 29914290
Recent studies have suggested an association between mutations in the IL-36RN gene and the onset of pustular generalized. In the literature, only one case of acute generalized exanthematous pustulosis (AGEP)...
9.
Sakka R, Mahjoub B, Kerkeni E, Werdani A, Boussoffara R, Cheikh H, et al.
Pediatr Blood Cancer
. 2018 May;
65(9):e27262.
PMID: 29797650
Poikiloderma with neutropenia (PN) is a genodermatosis characterized by poikiloderma, permanent neutropenia, recurrent infections, nail abnormalities, and palmoplantar hyperkeratosis. We report the case of a Tunisian patient with PN. Skin...
10.
Tounsi N, Trabelsi I, Kerkeni E, Grissa M, Fredj N, Sekma A, et al.
Pharmacology
. 2017 Feb;
99(5-6):250-258.
PMID: 28208135
Background: Digoxin is a substrate of P-glycoprotein (P-gp) and organic anion transporting polypeptide transporters that are encoded by ABCB1 and SLCO1B3 genes. Genetic polymorphisms in both genes may explain inter-individual...